BioWorld

Oct. 6, 2003

View Archived Issues

Cubist Signs Chiron As Ex-U.S. Partner For Cubicin Marketing

Ariad Gets $41M In Private Sale For Drug Development

Ligand Pulls Down $12.5M Through Royalty Agreement

Flamel Raises $62M Through Sale Of Its Common Shares

Receptor BioLogix Steering Lead Product Toward Gastric Cancer

Other News To Note

Asking For More Data, FDA Places Hold On DOV's Ocinaplon Phase III

The FDA placed a hold on DOV Pharmaceutical Inc.'s pivotal Phase III trial for an anti-anxiety candidate, asking for additional safety data. (BioWorld Today) Read More

Today's news in brief

BioWorld

BioWorld briefs for Jan 29, 2025.

Today's news in brief

BioWorld MedTech

BioWorld MedTech briefs for Jan. 29, 2026.

DNA mutations or genetic disorder concept art

Biallelic variants in COX18 identified as cause of Charcot-Marie-Tooth disease

BioWorld Science

Charcot-Marie-Tooth (CMT) disease is a group of clinically and genetically heterogeneous sensorimotor peripheral neuropathies. It is the most frequent inherited...

Brain-derived tau in blood predicts stroke severity and outcome

BioWorld Science

Brain-derived tau, a protein that is exclusive to the brain and detectable in the blood, could serve as an indicator of brain damage after an ischemic stroke. The...

Centessa’s CNT-9982 shows promise for MDD

BioWorld Science

Orexin OX2 receptor agonists have demonstrated the ability to enhance wakefulness in rodent models, as well as in nonhuman primates and patients with narcolepsy...